Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
April 04, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024 16:01 ET
|
Celcuity Inc.
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data...
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
March 20, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
March 06, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
February 28, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
February 22, 2024 16:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient...
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
February 20, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...
Orion Group Financial Statement Release January–December 2023
February 13, 2024 05:00 ET
|
Orion Oyj
ORION CORPORATION FINANCIAL STATEMENT RELEASE 1-12/2023 13 FEBRUARY 2024 at 12:00 EET Orion Group Financial Statement Release January–December 2023 Net sales totalled EUR 1,189.7...
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
February 05, 2024 09:00 ET
|
Yiviva
NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed...
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
January 08, 2024 09:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...